Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel T Barratt

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Clinical Pharmacology and Therapeutics|December 21, 2006
ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individualsJanet K Coller, Daniel T Barratt, Karianne Dahlen, et al.
Basic & Clinical Pharmacology & Toxicology|April 1, 2018
CYP3A5*3 and ABCB1 61A>G Significantly Influence Dose-adjusted Trough Blood Tacrolimus Concentrations in the First Three Months Post-Kidney TransplantationRong Hu, Daniel T Barratt, Janet K Coller, et al.
Pharmacogenetics and Genomics|November 30, 2018
Effect of tacrolimus dispositional genetics on acute rejection in the first 2 weeks and estimated glomerular filtration rate in the first 3 months following kidney transplantationRong Hu, Daniel T Barratt, Janet K Coller, et al.
Therapeutic Drug Monitoring|July 2, 2019
Is There a Temporal Relationship Between Trough Whole Blood Tacrolimus Concentration and Acute Rejection in the First 14 Days After Kidney Transplantation?Rong Hu, Daniel T Barratt, Janet K Coller, et al.
Frontiers in Pain Research (Lausanne, Switzerland)|July 9, 2026
Feasibility and reliability of pressure algometry for mechanical nociceptive threshold quantification in lambs in a field environmentCharlotte Helen Johnston, Danila Marini, Stefan T Musolino, et al.
British Journal of Clinical Pharmacology|June 18, 2019
High and variable population prevalence of HLA-B*56:02 in indigenous Australians and relation to phenytoin-associated drug reaction with eosinophilia and systemic symptomsAndrew A Somogyi, Daniel T Barratt, Elizabeth J Phillips, et al.
Pain|September 21, 2016
Ethnicity-dependent influence of innate immune genetic markers on morphine PCA requirements and adverse effects in postoperative painAndrew A Somogyi, Alex T Sia, Ene-Choo Tan, et al.
Clinical Pharmacology and Therapeutics|May 13, 2022
Population Pharmacokinetics and Pharmacodynamics of the Therapeutic and Adverse Effects of Ketamine in Patients With Treatment-Refractory DepressionAhmad Y Abuhelwa, Andrew A Somogyi, Colleen K Loo, et al.
Pharmacogenetics and Genomics|January 29, 2014
Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 cancer patients of the EPOS studyDaniel T Barratt, Benedikte Bandak, Pål Klepstad, et al.
Journal of Neurochemistry|June 16, 2012
Harnessing pain heterogeneity and RNA transcriptome to identify blood-based pain biomarkers: a novel correlational study design and bioinformatics approach in a graded chronic constriction injury modelPeter M Grace, Daniel Hurley, Daniel T Barratt, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Clinical Pharmacology and Therapeutics|December 21, 2006
ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individualsJanet K Coller, Daniel T Barratt, Karianne Dahlen, et al.
Basic & Clinical Pharmacology & Toxicology|April 1, 2018
CYP3A5*3 and ABCB1 61A>G Significantly Influence Dose-adjusted Trough Blood Tacrolimus Concentrations in the First Three Months Post-Kidney TransplantationRong Hu, Daniel T Barratt, Janet K Coller, et al.
Pharmacogenetics and Genomics|November 30, 2018
Effect of tacrolimus dispositional genetics on acute rejection in the first 2 weeks and estimated glomerular filtration rate in the first 3 months following kidney transplantationRong Hu, Daniel T Barratt, Janet K Coller, et al.
Therapeutic Drug Monitoring|July 2, 2019
Is There a Temporal Relationship Between Trough Whole Blood Tacrolimus Concentration and Acute Rejection in the First 14 Days After Kidney Transplantation?Rong Hu, Daniel T Barratt, Janet K Coller, et al.
Frontiers in Pain Research (Lausanne, Switzerland)|July 9, 2026
Feasibility and reliability of pressure algometry for mechanical nociceptive threshold quantification in lambs in a field environmentCharlotte Helen Johnston, Danila Marini, Stefan T Musolino, et al.
British Journal of Clinical Pharmacology|June 18, 2019
High and variable population prevalence of HLA-B*56:02 in indigenous Australians and relation to phenytoin-associated drug reaction with eosinophilia and systemic symptomsAndrew A Somogyi, Daniel T Barratt, Elizabeth J Phillips, et al.
Pain|September 21, 2016
Ethnicity-dependent influence of innate immune genetic markers on morphine PCA requirements and adverse effects in postoperative painAndrew A Somogyi, Alex T Sia, Ene-Choo Tan, et al.
Clinical Pharmacology and Therapeutics|May 13, 2022
Population Pharmacokinetics and Pharmacodynamics of the Therapeutic and Adverse Effects of Ketamine in Patients With Treatment-Refractory DepressionAhmad Y Abuhelwa, Andrew A Somogyi, Colleen K Loo, et al.
Pharmacogenetics and Genomics|January 29, 2014
Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 cancer patients of the EPOS studyDaniel T Barratt, Benedikte Bandak, Pål Klepstad, et al.
Journal of Neurochemistry|June 16, 2012
Harnessing pain heterogeneity and RNA transcriptome to identify blood-based pain biomarkers: a novel correlational study design and bioinformatics approach in a graded chronic constriction injury modelPeter M Grace, Daniel Hurley, Daniel T Barratt, et al.
Pageof 3